|
1
|
Anninga JK, Gelderblom H, Fiocco M, Kroep
JR, Taminiau AHM, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, He Z, Duan Y, Wang C, Kamar S,
Shi X, Yang J, Yang J, Zhao N, Han L, et al: Does intensified
chemotherapy increase survival outcomes of osteosarcoma patients? A
meta-analysis. J bone Oncol. 12:54–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang G, Yuan J and Li K: EMT transcription
factors: Implication in osteosarcoma. Med Oncol. 30:6972013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X and Lei X: Expression of Zeb1 and
Zeb2 indicates metastasis and unfavorable prognosis in
osteosarcoma. Int J Clin Exp Pathol. 10:611–617. 2017.
|
|
6
|
Eger A, Aigner K, Sonderegger S, Dampier
B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R:
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates
epithelial plasticity in breast cancer cells. Oncogene.
24:2375–2385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Browne G, Emre Sayan A and Tulchinsky E:
ZEB proteins link cell motility with cell cycle control and cell
survival in cancer. Cell Cycle. 9:886–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki HI, Young RA and Sharp PA:
Super-enhancer-mediated RNA processing revealed by integrative
microRNA network analysis. Cell. 168:1000–1014.e15. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gulino R, Forte S, Parenti R, Memeo L and
Gulisano M: MicroRNA and pediatric tumors: Future perspectives.
Acta Histochem. 117:339–354. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan H, Lu S, Wang S and Zhang S:
Identification of critical genes associated with human osteosarcoma
metastasis based on integrated gene expression profiling. Mol Med
Rep. 20:915–930. 2019.PubMed/NCBI
|
|
12
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Z, Li X, Yang Y, He Z, Qu X and Zhang
Y: Long noncoding RNAs in the progression, metastasis and prognosis
of osteosarcoma. Cell Death Dis. 7:e23892016. View Article : Google Scholar
|
|
14
|
Ergun S and Oztuzcu S: Oncocers:
ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways.
Tumor Biol. 36:3129–3136. 2015. View Article : Google Scholar
|
|
15
|
López-Urrutia E, Bustamante Montes LP,
Ladrón de Guevara Cervantes D, Pérez-Plasencia C and Campos-Parra
AD: Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs:
Deciphering molecular mechanisms of master regulators in cancer.
Front Oncol. 9:6692019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamura S, Imai-Sumida M, Tanaka Y and
Dahiya R: Interaction and cross-talk between non-coding RNAs. Cell
Mol Life Sci. 75:467–484. 2018. View Article : Google Scholar :
|
|
17
|
Karger S, Liu T, He S, Li Z and Dou P:
Application of long noncoding RNAs in osteosarcoma: Biomarkers and
therapeutic targets. Cell Physiol Biochem. 42:1407–1419. 2017.
View Article : Google Scholar
|
|
18
|
Li Z, Shen J, Chan MTV and Wu WKK: The
long non-coding RNA SPRY4IT1: An emerging player in tumorigenesis
and osteosarcoma. Cell Prolif. 51:e124462018. View Article : Google Scholar
|
|
19
|
Xu J, Ding R and Xu Y: Effects of long
non-coding RNA SPRY4-IT1 on osteosarcoma cell biological behavior.
Am J Transl Res. 8:5330–5337. 2016.
|
|
20
|
Guo F, Cogdell D, Hu L, Yang D, Sood AK,
Xue F and Zhang W: miR-101 suppresses the epithelial-to-mesenchymal
transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol
Rep. 31:2021–2028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X,
Wang M, Huang C, Wang L, Zeng F and Jiang G: LncRNA SPRY4-IT1
sponges miR-101-3p to promote proliferation and metastasis of
bladder cancer cells through up-regulating EZH2. Cancer Lett.
388:281–291. 2017. View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han L, Chen W, Xia Y, Song Y, Zhao Z,
Cheng H and Jiang T: miR-101 inhibits the proliferation and
metastasis of lung cancer by targeting zinc finger E-box binding
homeobox 1. Am J Transl Res. 10:1172–1183. 2018.PubMed/NCBI
|
|
25
|
Thomson DW and Dinger ME: Endogenous
microRNA sponges: Evidence and controversy. Nat Rev Genet.
17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Son H and Moon A: Epithelial-mesenchymal
transition and cell invasion. Toxicol Res. 26:245–252. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong TS, Gao W and Chan JY: Transcription
regulation of E-cadherin by zinc finger E-box binding homeobox
proteins in solid tumors. Biomed Res Int. 2014:9215642014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Daw NC, Chou AJ, Jaffe N, Rao BN, Billups
CA, Rodriguez-Galindo C, Meyers PA and Huh WW: Recurrent
osteosarcoma with a single pulmonary metastasis: A
multi-institutional review. Br J Cancer. 112:278–282. 2015.
View Article : Google Scholar :
|
|
30
|
Sánchez Y and Huarte M: Long non-coding
RNAs: Challenges for diagnosis and therapies. Nucleic Acid Ther.
23:15–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Faruq O and Vecchione A: microRNA:
Diagnostic Perspective. Front Med (Lausanne). 2:512015.
|
|
32
|
Yao ZS, Li C, Liang D, Jiang XB, Tang JJ,
Ye LQ, Yuan K, Ren H, Yang ZD, Jin DX, et al: Diagnostic and
prognostic implications of serum miR-101 in osteosarcoma. Cancer
Biomark. 22:127–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li
C, Kang P, Leng K, Ji D, Li Z, et al: SP1-induced upregulation of
lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding
EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J
Exp Clin Cancer Res. 37:812018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin J, Chu Z, Ma P, Meng Y and Yang Y:
Long non-coding RNA SPRY4-IT1 promotes proliferation and invasion
by acting as a ceRNA of miR-101-3p in colorectal cancer cells.
Tumor Biol. 39:10104283177162502017. View Article : Google Scholar
|
|
35
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-101 inhibits proliferation, migration and invasion in
osteosarcoma cells by targeting ROCK1. Am J Cancer Res. 7:88–97.
2017.PubMed/NCBI
|
|
37
|
Lin H, Zheng X, Lu T, Gu Y, Zheng C and
Yan H: The proliferation and invasion of osteosarcoma are inhibited
by miR-101 via targetting ZEB2. Biosci Rep. 39:BSR201812832019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
